^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + pamvatamig (MCLA-129) (EGFR inhibitor, c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
516MO - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
Published date:
11/27/2023
Excerpt:
DCR was 90% (95% CI 56-100). In 2L+, 11/22 evaluable pts had PR (50%; 95% CI 28-72), 6 confirmed. 9/11 PRs were ongoing. DCR was 82% (95% CI 60-95)….MCLA-129 plus osimertinib showed promising clinical efficacy in EGFRmut NSCLC, in 1L and 2L+.
Trial ID:
